Medical Condition News

RSS

UB scientists propose first genomic explanation for schizophrenia

New University at Buffalo research demonstrates how defects in an important neurological pathway in early development may be responsible for the onset of schizophrenia later in life.

23 Jan 2013

Insight into mechanical properties that break the outer segment of photoreceptors

Light-sensing cells in the eye rely on their outer segment to convert light into neural signals that allow us to see. But because of its unique cylindrical shape, the outer segment is prone to breakage, which can cause blindness in humans. A study published by Cell Press on January 22nd in the Biophysical Journal provides new insight into the mechanical properties that cause the outer segment to snap under pressure.

23 Jan 2013

Very low levels of BPS can disrupt natural estrogen hormone actions

A few years ago, manufacturers of water bottles, food containers, and baby products had a big problem. A key ingredient of the plastics they used to make their merchandise, an organic compound called bisphenol A, had been linked by scientists to diabetes, asthma and cancer and altered prostate and neurological development.

23 Jan 2013

IntelliCell receives U.S. patent allowance for ultrasonic cavitation method

IntelliCell BioSciences, Inc. announced that on January 17, 2013 the Company received a notice of allowance regarding its U.S. Patent Application Serial No. 13/323,030 entitled "Ultrasonic Cavitation of Adipose Tissue to Produce Stromal Vascular Fraction Regenerative Cells."

23 Jan 2013

STA announces results from ABRAXANE plus gemcitabine phase III trial on pancreatic cancer

Australian biopharmaceutical company Specialised Therapeutics Australia announces that a phase III clinical trial of world leading breast cancer drug ABRAXANE (nanoparticle albumin-bound paclitaxel) in combination with current standard of care gemcitabine in patients with advanced pancreatic cancer has demonstrated substantially improved survival times, with double the number of patients surviving two years.

23 Jan 2013

Study offers first detailed map of brain regions that contribute to emotional intelligence

A new study of 152 Vietnam veterans with combat-related brain injuries offers the first detailed map of the brain regions that contribute to emotional intelligence - the ability to process emotional information and navigate the social world.

22 Jan 2013

ParseCNV software can detect disease-causing copy number variations

A novel software tool, developed at The Children's Hospital of Philadelphia, streamlines the detection of disease-causing genetic changes through more sensitive detection methods and by automatically correcting for variations that reduce the accuracy of results in conventional software.

22 Jan 2013

Pregnant women with hypertensive disorders more likely to develop end-stage renal disease

Women with hypertensive disorders in pregnancy are at higher risk of chronic kidney disease and end-stage renal disease compared with women without the disorders, according to a study in CMAJ (Canadian Medical Association Journal).

22 Jan 2013

Researchers develop software package that adapts Facebook for visually impaired people

This new software was developed by researchers at the Department of Programming Languages and Systems of the University of Granada.. So far, there were only special social networks specifically developed for visually impaired people, such as Blindworlds. Researchers at the University of Granada have developed a software package that adapts Facebook for visually impaired people.

22 Jan 2013

Brown biology professor named Pew's Scholar of the Month

Biologist Erica Larschan, Ph.D., was named by The Pew Charitable Trusts as the "Scholar of the Month," for her innovative findings on chromosomal activity in fruit flies.

22 Jan 2013

Intelligent algorithms for programming deep brain stimulation in Parkinson’s to be developed by Great Lakes NeuroTechnologies

Great Lakes NeuroTechnologies (GLNT) announced today that they are launching a study to determine the feasibility of using intelligent algorithms to assist with programming deep brain stimulation settings for Parkinson’s disease.

22 Jan 2013

Chronic heart failure treatment, Inspra (eplerenone), accepted for use within NHS Wales

Inspra (eplerenone) has now been accepted by the All Wales Medicines Strategy Group (AWMSG) for use in adult patients with chronic heart failure (CHF) NYHA class II, in combination with standard optimal therapy...

22 Jan 2013

Psychiatrist claims medical marijuana dangerous for treatment of psychiatric problems

Using medical marijuana to treat conditions such as anxiety and depression is dangerous and has no basis in medical science, says Dr. Timothy R. Jennings, a prominent Tennessee psychiatrist and consultant to The Center for Counseling and Health Resources in Edmonds, WA.

22 Jan 2013

Calmangafodipir protects against side effects of cancer treatments

A drug developed at Linköping University in Sweden protects against the side effects of cancer treatments while strengthening the effects on the tumour.

22 Jan 2013

New special issue explores link between evolution and the body's fight against cancer

Over 500 billion cells in our bodies will be replaced daily, yet natural selection has enabled us to develop defenses against the cellular mutations which could cause cancer. It is this relationship between evolution and the body's fight against cancer which is explored in a new special issue of the Open Access journal Evolutionary Applications.

22 Jan 2013

Russia approves FzioMed’s Oxiplex gel for lumbar spine surgery

FzioMed, a privately held medical device company based in San Luis Obispo, CA., is pleased to announce the approval of Oxiplex in Russia. Oxiplex is an absorbable, clear, viscoelastic gel that is applied during lumbar spine surgery immediately prior to wound closure.

22 Jan 2013

Synthon Biopharmaceuticals announces promising results with its antibody-drug conjugate program

Synthon Biopharmaceuticals, a subsidiary of specialty pharma company Synthon, has reported promising results with its lead program of antibody-drug conjugates (ADCs).

22 Jan 2013

FDA approves Ampio’s IND for Optina for treatment of diabetic macular edema

Ampio Pharmaceuticals, Inc. announced today that the FDA has accepted the Company's IND for Optina™ for the treatment of diabetic macular edema (DME). Ampio plans to commence enrollment in a clinical trial in the first quarter of 2013. The FDA granted Optina™ 505(b)(2) status in July, 2012. Drugs designated under this pathway can be approved on a single trial.

22 Jan 2013

Rainbow Coral visits genome-mapping facility in Houston

Since the new year began, Rainbow Coral Corp. has wasted no time in searching for new targets to add to its portfolio of projects for commercialization. Last week, the Company's executive leadership accepted an invitation to tour a genome-mapping facility in Houston with which RBCC could soon partner.

22 Jan 2013

Family members with rare gene mutation at high risk of developing schizophrenia

Johns Hopkins researchers have identified a rare gene mutation in a single family with a high rate of schizophrenia, adding to evidence that abnormal genes play a role in the development of the disease.

22 Jan 2013

Medical Condition News

UB scientists propose first genomic explanation for schizophrenia

Insight into mechanical properties that break the outer segment of photoreceptors

Very low levels of BPS can disrupt natural estrogen hormone actions

IntelliCell receives U.S. patent allowance for ultrasonic cavitation method

STA announces results from ABRAXANE plus gemcitabine phase III trial on pancreatic cancer

Study offers first detailed map of brain regions that contribute to emotional intelligence

ParseCNV software can detect disease-causing copy number variations

Pregnant women with hypertensive disorders more likely to develop end-stage renal disease

Researchers develop software package that adapts Facebook for visually impaired people

Brown biology professor named Pew's Scholar of the Month

Intelligent algorithms for programming deep brain stimulation in Parkinson’s to be developed by Great Lakes NeuroTechnologies

Chronic heart failure treatment, Inspra (eplerenone), accepted for use within NHS Wales

Psychiatrist claims medical marijuana dangerous for treatment of psychiatric problems

Calmangafodipir protects against side effects of cancer treatments

New special issue explores link between evolution and the body's fight against cancer

Russia approves FzioMed’s Oxiplex gel for lumbar spine surgery

Synthon Biopharmaceuticals announces promising results with its antibody-drug conjugate program

FDA approves Ampio’s IND for Optina for treatment of diabetic macular edema

Rainbow Coral visits genome-mapping facility in Houston

Family members with rare gene mutation at high risk of developing schizophrenia

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Latest News